March 08, 2021
1 min read
Save
HF, COVID-19 therapies among those featured in ACC.21 late-breakers
The American College of Cardiology announced its lineup of late-breaking clinical trials selected for presentation at its virtual 2021 Scientific Session.
Among the topics to be covered at the session, which will be held from May 15 through 17, are sacubitril/valsartan (Entresto, Novartis) vs. ACE inhibitors to reduce HF events after MI; long-term effectiveness of aspirin therapy; dapagliflozin (Farxiga, AstraZeneca) for prevention of events and improved recovery in patients with respiratory failure from COVID-19; and sotagliflozin (Zynquista, Lexicon/Sanofi) for the treatment of HF regardless of ejection fraction.
The following presentations were among those selected as late-breakers:
- PARADISE-MI, a trial comparing sacubitril/valsartan and ACE inhibitors for reduction of HF events in patients with MI;
- ADAPTABLE, a patient-centric trial assessing dosing and long-term benefits of aspirin;
- DARE-19, a randomized trial of dapagliflozin for the prevention of major clinical events and recovery in patients with respiratory failure due to COVID-19;
- REHAB-HF, which assessed a novel physical rehabilitation intervention for older patients with acute decompensated HF;
- the PRADA study of candesartan and metoprolol for the prevention of cardiac dysfunction during adjuvant breast cancer therapy;
- FLOWER-MI, a randomized controlled trial that assessed fractional flow reserve-guided vs. angio-guided multivessel revascularization in STEMI;
- the RADIANCE-HTN TRIO trial, which compared endovascular ultrasound renal denervation to for triple therapy resistant hypertension;
- an evaluation of sotagliflozin across ejection fraction subgroups, including HF with preserved ejection fraction;
- CONNECT-HF, a randomized trial to assess HF care optimization via patient and hospital engagement;
- the LIFE trial, which looked at the effects of sacubitril/valsartan in patients with advanced HF with reduced EF;
- a secondary analysis from GALACTIC-HF, which analyzed the impact of EF on the therapeutic effect of omecamtiv mecarbil (Amgen/Cytokinetics/Servier) in HFrEF;
- a randomized trial of therapeutic hypothermia following out-of-hospital cardiac arrest;
- a study on acute alcohol consumption and discrete atrial fibrillation events; and
- the RAFT-AF randomized trial, which compared ablation-based AF rhythm control with rate control in patients with HF and a high burden of AF.